Acting on the cytokine cascade is key to preventing disease progression and death in
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …

The global pandemic from COVID-19 infection has generated significant public health
concerns, both health-wise and economically. There is no specific pharmacological antiviral …

Background Immunosuppressive and anti-cytokine treatment may have a protective effect for
patients with COVID-19. Understanding the immune cell states shared between COVID-19 …

Abstract Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive inflammatory
responses following tissue damage or infection and is a promising target for treatment of …

A global pandemic has erupted as a result of the new brand coronavirus, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). This pandemic has been consociated …

Although interest in “cytokine storms” has surged over the past decade, it was massively
amplified in 2020 when it was suggested that a subset of patients with COVID-19 developed …

Eosinophils are bone marrow-derived granulocytes that, under homeostatic conditions,
account for as much as 1-3% of peripheral blood leukocytes. During inflammation …

Abstract Background Coronavirus disease 19 (COVID-19) may have a severe course in
children. Multisystem inflammatory syndrome in children (MIS-C) is the post-COVID …

Post‐acute sequelae of COVID‐19 (PASC) are long‐term consequences of SARS‐CoV‐2
infection that can substantially impair the quality of life. Underlying mechanisms ranging …

Objective: The increased level of interleukin (IL)-33 is considered as a predictor of severe
coronavirus disease 2019 (COVID-19) infection, but its role at different stages of the disease …